The generation of leukemic dendritic cells from acute myeloid leukemia cells is potentiated by the addition of CD40L at the terminal maturation stage
Corresponding Author
Je-Jung Lee
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea
Hematology/Oncology Clinics, Chonnam National University Hwasun Hospital, 160 Ilshimri, Hwasun, Jeonnam, 519-809, South KoreaSearch for more papers by this authorBo-Hwa Choi
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorJong-Hee Nam
Department of Pathology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorMyong-Suk Park
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorWon-Hyun Song
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorDeok-Hwan Yang
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorYeo-Kyeoung Kim
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorSang-Hee Cho
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorIk-Joo Chung
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorKyeong-Soo Park
Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea
Search for more papers by this authorII-Kwon Lee
Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea
Search for more papers by this authorHyeoung-Joon Kim
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea
Search for more papers by this authorCorresponding Author
Je-Jung Lee
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea
Hematology/Oncology Clinics, Chonnam National University Hwasun Hospital, 160 Ilshimri, Hwasun, Jeonnam, 519-809, South KoreaSearch for more papers by this authorBo-Hwa Choi
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorJong-Hee Nam
Department of Pathology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorMyong-Suk Park
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorWon-Hyun Song
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorDeok-Hwan Yang
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorYeo-Kyeoung Kim
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorSang-Hee Cho
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorIk-Joo Chung
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Search for more papers by this authorKyeong-Soo Park
Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea
Search for more papers by this authorII-Kwon Lee
Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea
Search for more papers by this authorHyeoung-Joon Kim
Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea
Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea
Search for more papers by this authorAbstract
Leukemic dendritic cells (DCs) that are derived from acute myeloid leukemia (AML) cells display low-level expression of several key molecules. We investigated the optimal combination of cytokines needed to generate potent leukemic DCs from AML cells in vitro. AML cells were cultured in the presence of the following combinations of cytokines: Group A, granulocyte-macrophage colony-stimulating factor (GM-CSF) + interleukin-4 (IL-4) + tumor necrosis factor-alpha (TNF-α); Group B, GM-CSF + IL-4 + CD40L; and Group C, CD40L addition at the terminal maturation point of cells that were grown as for Group A. The AML cells showed clear upregulation of CD80, CD83, CD86, CD40, and HLA-DR expression under all culture conditions, without significant differences between these groups. However, the addition of CD40L (as in Group C) showed a slight upregulation in the expression of CD83 and CD86 on leukemic DCs. The leukemic DCs in Groups A and B had higher allogeneic T-cell stimulatory capacities than untreated AML cells, and the addition of CD40L (Group C) enhanced this effect. The function of the cytotoxicity-stimulating autologous T cells was also augmented by the addition of CD40L (Group C). These results suggest that AML cells may be used to generate leukemic DCs using various cytokine combinations, and that the most potent, mature leukemic DCs are generated by the addition of CD40L to terminal-stage AML cultures that are grown in the presence of conventional cytokine combinations. J. Clin. Apheresis 19:130–136, 2004. © 2004 Wiley-Liss, Inc.
REFERENCES
- 1 Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062.
- 2 Burnett AK, Kell J, Rowntree C. Acute myeloid leukemia: therapeutic indications. Curr Opin Hematol 2000; 7: 333–338.
- 3 Hirano N, Takahashi T, Ohtake S, Hirashima K, Emi N, Saito K, Hirano M, Shinohara K, Takeuchi M, Taketazu F, Tsunoda S, Ogura M, Omine M, Saito T, Yazaki Y, Ueda R, Hirai H. Expression of costimulatory molecules in human leukemias. Leukemia 1996; 10: 1168–1176.
- 4 Notter M, Willinger T, Erben U, Thiel E. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood 2001; 97: 3138–3145.
- 5 Buzyn A, Petit F, Ostankovitch M, Figueiredo S, Varet B, Guillet JG, Ameisen JC, Estaquier J. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients. Blood 1999; 94: 3135–3140.
- 6 Buggins AG, Lea N, Gaken J, Darling D, Farzaneh F, Mufti GJ, Hirst WJ. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. Blood 1999; 94: 3479–3490.
- 7 Reid DC. Dendritic cells and immunotherapy for malignant disease. Br J Haematol 2001; 112: 874–887.
- 8 Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245–3287.
- 9 Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–252.
- 10 Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999; 93: 780–786.
- 11 Harrison BD, Adams JA, Briggs M, Brereton ML, Yin JA. Stimulation of autologous proliferative and cytotoxic T-cell responses by “leukemic dendritic cells” derived from blast cells in acute myeloid leukemia. Blood 2001; 97: 2764–2771.
- 12 Waclavicek M, Berer A, Oehler L, Stockl J, Schloegl E, Majdic O, Knapp W. Calcium ionophore: a single reagent for the differentiation of primary human acute myelogenous leukaemia cells towards dendritic cells. Br J Haematol 2001; 114: 466–473.
- 13 Koski GK, Schwartz GN, Weng DE, Gress RE, Engels FH, Tsokos M, Czerniecki BJ, Cohen PA. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. Blood 1999; 94: 1359–1371.
- 14 McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, Calabresi P, Ha T, Tran TV, Tate KM, Winkelhake J, Spack EG. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997; 210: 149–166.
- 15 Lee JJ, Takei M, Hori S, Inoue Y, Harada Y, Tanosaki R, Kanda Y, Kami M, Makimoto A, Mineishi S, Kawai H, Shimosaka A, Heike Y, Ikarashi Y, Wakasugi H, Takaue Y, Hwang TJ, Kim HJ, Kakizoe T. The role of PGE(2) in the differentiation of dendritic cells: how do dendritic cells influence T-cell polarization and chemokine receptor expression? Stem Cells 2002; 20: 448–459.
- 16 Lee JJ, Nam CE, Nam JH, Lee HC, Chung IJ, Park MS, Choi BH, Song WH, Lee IK, Park KS, Kook H, Hwang TJ, Takei M, Takaue Y, Kim HJ. Generation of cytotoxic donor CD8+ T cells against relapsing leukemic cells following allogeneic transplantation by the stimulation with leukemic cell- or leukemic lysate pulsed donor cell-derived dendritic cells. Leuk Res 2004; 28: 517–524.
- 17
Charbonnier A,
Gaugler B,
Sainty D,
Lafage-Pochitaloff M,
Olive D.
Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias.
Eur J Immunol
1999;
29;
2567–2578.
10.1002/(SICI)1521-4141(199908)29:08<2567::AID-IMMU2567>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 18 Galea-Lauri J. Immunological weapons against acute myeloid leukaemia. Immunology 2002; 107: 20–27.
- 19 Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 2002; 51: 299–310.
- 20 Marten A, Renoth S, von Lilienfeld-Toal M,Buttgereit P,Schakowski F,Glasmacher A,Sauerbruch T,Schmidt-Wolf IG. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 2001; 86: 1029–1037.
- 21 Margolin KA, Negrin RS, Wong KK, Chatterjee S, Wright C, Forman SJ. Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 1997; 157: 231–240.
- 22 Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 1994; 87: 453–458.
- 23 Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood 1995; 86: 3493–3499.
- 24 Lee JJ, Kook H, Park MS, Nam JH, Choi BH, Song WH, Kim YK, Park KS, Lee IK, Chung IJ, Hwang TJ, Kim HJ. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apheresis 2004 (in press).
- 25 Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93: 2336–2341.
Citing Literature
